Reuters reports: The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions’ smallpox vaccine for use in people at high risk of mpox infection, sending the drugmaker’s shares 5% higher on Friday. The FDA clearance, announced late on Thursday by the company, makes the vaccine – called ACAM2000 – the second approved shot against mpox in the U.S. …
Read More »